Aslıhan ULU, Ayşe Seza İNAL, Behice KURTARAN, Aysun UĞUZ, Yeşim TAŞOVA, Süheyla KÖMÜR, Hasan Salih Zeki AKSU

Mucormycosis: a 10-year experience at a tertiary care center in Turkey

Background/aim: Mucormycosis is a rare invasive fungal infection most commonly encountered in the immunocompromised host. We analyzed 51 adult patients treated for mucormycosis between 2003 and 2013 and recorded at a tertiary university hospital in Turkey. Materials and methods: We examined the following data for all patients: age, sex, predisposing disease, symptoms, treatment, surgical procedure, concomitant infections, intensive care requirement, and outcomes. Results: During the study period 51 cases of mucormycosis were documented; 54.9% of the patients were female. The mean age was 44.2 ± 18.2 years. Rhinocerebral presentation was reported in 94.1% of patients. Almost all patients (88.2%) had at least one risk factor. The common predisposing factors were hematologic malignancies (52.9%), diabetes mellitus (25.5%), and solid malignancies (5.8%). The most common initial symptoms were fever, cellulitis, and facial pain. The primary medication used was liposomal amphotericin B or conventional amphotericin B. Surgery was performed in 94.1% of patients. Mortality was 52.9%. Conclusion: Our study revealed that mucormycosis continues to be a mortal disease in about half of the cases. Our findings indicate that treatment with L-AMB is associated with a favorable response. Also, in the case of facial pain, the low mortality rate may indicate the importance of early diagnosis.

PDF

___

1. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 1): 2334.
2. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634653.
3. Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008; 61: i35i39.
4. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009; 48: 17431751.
5. Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrau K, Lass-Florl C, Bouza E, Klimko N, Gaustad P et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17: 18591867.
6. Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, Desenclos JC, Lortholary O. Increasing incidence of zygomycosis (mucormycosis), France. Emerg Infect Dis 2005; 41: 634653.
7. Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Inf Dis 2010; 14: 100103.
8. Kara O, Tasova Y, Uguz A, Sahin B. Mucormycosis-associated fungal infections in patients with haematological malignancies. Int J Clin Prac 2009; 63: 134139.
9. Arda B, Erdem A, Sipahi OR, Işıkgöz Taşbakan M, Pullukçu H, Taşbakan MS, Ceylan N, Metin DY, Midilli R, Yamazhan T et al. Mucormycosis: a retrospective evaluation of 12 cases. Mikrobiyol Bul 2011; 45: 504511.
10. Ketenci I, Unlu Y, Kaya H, Somdaş MA, Kontaş O, Öztürk M, Vural A. Rhinocerebral mucormycosis: experience in 14 patients. J Laryngol Otol 2011; 125: 19.
11. Zeka AN, Taşbakan M, Pullukçu H, Sipahi OR, Yamazhan T, Arda B. Evaluation of zygomycosis cases by pooled analysis method reported from Turkey. Mikrobiyol Bul 2013; 47: 708 716.
12. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 13501360.
13. Mignogna MD, Fortuna G, Leuci S, Adamo D, Ruoppo E, Siano M, Mariani U. Mucormycosis in immunocompetent patients: a case-series of patients with maxillary sinus involvement and critical review of the literature. Int J Infect Dis 2011; 15: 533 540.
14. Radner AB, Witt MD, Edwards JE Jr. Acute invasive rhinocerebral zygomycosis in an otherwise healthy patient: case report and review. Clin Infect Dis 1995; 20: 163166.
15. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL; European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98: 492504.
16. Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20 (Suppl. 3): 526.
17. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE Jr. Liposomal amphotericin B and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob Agents Chemother 2003; 47: 33433344.
18. Vehreschild JJ, Birtel A, Vehreschild MJ, Liss B, Farowski F, Kochanek M, Sieniawski M, Wahlers F, Fatkenheuer G, Cornerly OA. Mucormycosis treated with posaconazole: a review of 96 case reports. Crit Rev Microbiol 2013; 39: 310324.
19. Tedder M, Spratt JA, Anstad MP, Hedge SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57: 10441050.
20. Vironneau P, Verillaud B, Tran H, Altabaa K, Blancal JP, Sauvaget E, Herman P, Kania R. Rhino-orbito-cerebral mucormycosis, surgical treatment, state of the art. Med Sci 2013; 29: 3135.
21. Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, Ibrahim AS, Brass EP. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012; 50: 611618.
22. Petrikos G, Skiada A, Sambatakou H, Toskas A, Vaiopoulos G, Giannopoulou M, Katsilambros N. Mucormycosis: tenyear experience at a tertiary-care center in Greece. Eur J Clin Microbiol Infect Dis 2003; 22: 753756.
23. Petrikos G, Skiada A, Drogari-Apiranthitou M. Epidemiology of mucormycosis in Europe. Clin Microbiol Infect 2014; 20 (Suppl. 6): 6773.
24. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, Bitar D, Dromer F, Lortholary O; French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (20052007). Clin Infect Dis 2012; 54 (Suppl. 1): S35S43.
25. Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Förl C, Beisel C, Herbrecht R, Roth Y, Silling G, Ullmann AJ et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65: 296302.